Albert D. Fraser
Department of Pathology and Laboratory Medicine
Queen Elizabeth II Health Sciences Center
Halifax
Nova Scotia
Canada
Name/email consistency: high
- Doping control from a global and national perspective. Fraser, A.D. Ther. Drug. Monit (2004)
- Urinary excretion profiles of 11-nor-9-carboxy-delta9-tetrahydrocannabinol and 11-hydroxy-delta9-THC: cannabinoid metabolites to creatinine ratio study IV. Fraser, A.D., Worth, D. Forensic Sci. Int. (2004)
- Urinary excretion profiles of 11-nor-9-carboxy-Delta9-tetrahydrocannabinol: a Delta9-THC-COOH to creatinine ratio study #2. Fraser, A.D., Worth, D. Forensic Sci. Int. (2003)
- Urinary excretion profiles of 11-nor-9-carboxy-Delta9-tetrahydrocannabinol. Study III. A Delta9-THC-COOH to creatinine ratio study. Fraser, A.D., Worth, D. Forensic Sci. Int. (2003)
- Impact of lowering the screening and confirmation cutoff values for urine drug testing based on dilution indicators. Fraser, A.D., Zamecnik, J. Ther. Drug. Monit (2003)
- Monitoring urinary excretion of cannabinoids by fluorescence-polarization immunoassay: a cannabinoid-to-creatinine ratio study. Fraser, A.D., Worth, D. Ther. Drug. Monit (2002)
- Drug and chemical metabolites in clinical toxicology investigations: the importance of ethylene glycol, methanol and cannabinoid metabolite analyses. Fraser, A.D., Coffin, L., Worth, D. Clin. Biochem. (2002)